Modeling of transfer kinetics at the serum-cerebrospinal fluid barrier in rabbits with experimental meningitis: Application to grepafloxacin

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 1, 2003, Pages 138-143

  Pfister, Marc ^c   Zhang, Liping ^c   Hammarlund Udenaes, Margareta ^b   Sheiner, Lewis B ^c   Gerber, Cynthia M ^a   Täuber, Martin G ^a   Cottagnoud, Philippe ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UPPSALA UNIVERSITY   (Sweden)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

GREPAFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL MENINGITIS; BLOOD CEREBROSPINAL FLUID BARRIER; COMPARTMENT MODEL; DOSE RESPONSE; DRUG CLEARANCE; DRUG DIFFUSION; MODEL; NONHUMAN; PRIORITY JOURNAL; RABBIT; SIMULATION;

ANIMALS; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; FLUOROQUINOLONES; MENINGITIS, PNEUMOCOCCAL; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PIPERAZINES; RABBITS;

EID: 12244253779     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.1.138-143.2003     Document Type: Article

References (32)

1. Anderson, B. J., N. H. G. Holford, G. A. Woollard, and P. L. S. Chan. 1998. Paracetamol plasma and cerebrospinal fluid pharmocokinetics in children. Br. J. Clin. Pharmacol. 46:237-243.
2. Andes, D., and W. A. Craig. 2002. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infections. Antimicrob. Agents Chemother. 46:1665-1670.
3. Barry, A. L., and F. C. Fuchs. 1997. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin. J. Chemother. 9:9-16.
4. Beal, S., and L. B. Sheiner. 1980. The NONMEM system. Am. Stat. 34:118-119.
5. Beal, S., and L. B. Sheiner (ed.). 1998. NONMEM users guides. NONMEM Project Group, University of California at San Francisco.
6. Bickel, P. J., and K. A. Doksum. 1976. Likelihood ratio tests and related procedures, p. 192-247. In E. L. Lehmann (ed.) Mathematical statistics: basic ideas and selected topics. Holden-Day, Inc., San Francisco, Calif.
7. Blondeau, J. M. 1999. Expanded activity and utility of the new fluoroquinolones: a review. Clin. Ther. 21:3-40.
8. Child, J., J. M. Andrews, and R. Wise. 1995. Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin. Antimicrob. Agents Chemother. 39:513-515.
9. Cordon-Cardo, C., J. P. O'Brien, D. Casals, L. Rittman-Grauer, J. L. Biedler, M. R. Melamed, and J. R. Bertino. 1989. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA 86:695-698.
10. Cottagnoud, P., F. Acosta, M. Cottagnoud, M. Pfister, and M. G. Täuber. 2002. Efficacy of BMS 284756 against penicillin-sensitive, penicillin-resistant, and quinolone-resistant pneumococci in experimental meningitis. Antimicrob. Agents Chemother. 46:184-187.
11. Dacey, R. G., and M. A. Sande. 1974. Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives. Antimicrob. Agents Chemother. 6:437-441.
12. De Vries, H. E., J. Kuiper, A. G. De Boer, T. J. C. Van Berkel, and D. D. Breimer. 1997. The blood-brain barrier in neuroinflammatory diseases. Pharmacol. Rev. 49:143-155.
13. Efthymiopoulos, C. 1997. Pharmacokinetics of grepafloxacin. J. Antimicrob. Chemother. 40:35-43.
14. Gerber, C. M., L. Tovar, M. Cottagnoud, K. Neftel, M. G. Täuber, and P. Cottagnoud. 2000. Grepafloxacin against penicillin-resistant pneumococci in the rabbit meningitis model. J. Antimicrob. Chemother. 46:249-253.
15. Hammarlund-Udenaes, M. 2000. The use of microdialysis in CNS drug delivery studies. Pharmacokinetic perspectives and results with analgesics and antiepileptics. Adv. Drug Deliv. Rev. 45:283-294.
16. Karol, M. D., P. V. Pedersen, and R. E. Brashear. 1983. Diffusion and flow transfer of theophylline across the blood-brain barrier: pharmacokinetic analysis. J. Pharmacokinet. Biopharm. 11:273-287.
17. Kawakami, J., K. Yamamoto, Y. Sawada, and T. Iga. 1994. Prediction of brain delivery of ofloxacin, a new quinolone, in the human from animal data. J. Pharmacokinet. Biopharm. 22:207-227.
18. Kim, Y. S., Q. Liu, L. L. Chow, and M. G. Täuber. 1997. Trovafloxacin in treatment of rabbits with experimental meningitis caused by high-level penicillin-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:1186-1189.
19. Nau, R., T. Schmidt, K. Kaye, J. L. Froula, and M. G. Täuber. 1995. Quinolone antibiotics in therapy of experimental pneumococcal meningitis in rabbits. Antimicrob. Agents Chemother. 39:593-597.
20. Nau, R., F. Sorgel, and H. W. Prange. 1998. Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections. Clin. Pharmacokinet. 35:223-246.
21. Ooie, T., H. Suzuki, T. Tetsuya, and Y. Sugiyama. 1996. Kinetics of quinolone antibiotics in rats: efflux from cerebrospinal fluid to the circulation. Pharm. Res. 7:1065-1068.
22. Pollay, M., and H. Davson. 1963. The passage of certain substances out of the cerebrospinal fluid. Brain 86:137-150.
23. Rodriguez-Cerrato, V., C. C. McCoig, I. C. Michelow, F. Ghaffar, H. S. Jafri, R. D. Hardy, C. Patel, K. Olsen, and G. H. McCracken. 2001. Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis. Antimicrob. Agents Chemother. 45:3092-3097.
24. Scheld, W. M., R. G. Dacey, H. R. Winn, J. E. Welsh, J. A. Jane, and M. A. Sande. 1980. Cerebrospinal fluid outflow resistance in rabbits with experimental meningitis: alterations with penicillin and methylprednisolone. J. Clin. Investig. 66:243-253.
25. Scheld, W. M. 1991. Evaluation of quinolones in experimental animal models of infections. Eur. J. Clin. Microbiol. Infect. Dis. 10:275-290.
26. Schinkel, A. H., E. Wagenaar, L. Van Deemter, C. A. Mol, and P. Borst. 1995. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Investig. 96:1698-1705.
27. Sheiner, L. B., and J. C. Wakefield. 1999. Population modeling in drug development. Stat. Methods Med. Res. 8:183-193.
28. Simon, H. J., and E. J. Yin. 1970. Microbioassay of antimicrobial agents. Appl. Microbiol. 19:573-579.
29. Tanaka, M., K. Hoshino, M. Hohmura, H. Ishida, A. Kitamura, K. Sato, I. Hayakawa, and T. Nishino. 1996. Effect of growth conditions on antimicrobial activity of DU-6859a and its bactericidal activity determined by the killing curve method. J. Antimicrob. Chemother. 37:1091-1102.
30. Welch, K. 1963. Secretion of cerebrospinal fluid by choroids plexus of the rabbit. Am. J. Physiol. 205:617-624.
31. Wise, R. 1998. Grepafloxacin: pharmacokinetics and tissue penetration. Clin. Microbiol. Infect. 4:S21-S24.
32. Zhang, L., R. Price, F. Aweeka, E. Bellibas, and L. B. Sheiner. 2001. Making the most of sparse clinical data by using predictive-model-based analysis, illustrated with a stavudine pharmacokinetic study. Eur. J. Pharm. Sci. 12: 377-385.